• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Viracta Therapeutics Inc.

    2/13/24 9:04:25 PM ET
    $VIRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VIRX alert in real time by email
    SC 13G 1 d744273dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No.  )*

     

     

    Viracta Therapeutics, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    92765F108

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d–1(b)

    ☐ Rule 13d–1(c)

    ☒ Rule 13d–1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No.             Page 1 of 5

     

     (1)   

    Names of reporting persons

     

    Forward Ventures V, L.P.

     (2)  

    Check the appropriate box if a member of a group

    (a) ☐  (b) ☐ (see instructions)

     

     (3)  

    SEC use only

     

     (4)  

    Citizenship or place of organization

     

    Delaware

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person

    with:

       (5)    

    Sole voting power

     

    2,567,522 shares, except that Forward V Associates, LLC, (“Forward GP”) the general partner of Forward Ventures V, L.P., may be deemed to have sole power to vote these shares, and Standish M. Fleming, the managing member of Forward GP, may be deemed to have shared power to vote these shares.

       (6)   

    Shared voting power

     

    See response to row 5.

       (7)   

    Sole dispositive power

     

    2,567,522 shares, except that Forward GP the general partner of Forward Ventures V, L.P., may be deemed to have sole power to dispose of these shares, and Standish M. Fleming, the managing member of Forward GP, may be deemed to have sole power to dispose of these shares.

       (8)   

    Shared dispositive power

     

    See response to row 7.

     (9)   

    Aggregate amount beneficially owned by each reporting person

     

    2,567,522

    (10)  

    Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

     

    (11)  

    Percent of class represented by amount in Row (9)

     

    6.65%

    (12)  

    Type of reporting person (see instructions)

     

    PN


       SCHEDULE 13G    Page 2 of 5

     

    Item 1(a)

    Name of issuer: Viracta Therapeutics, Inc. (the “Issuer”)

     

    Item 1(b)

    Address of issuer’s principal executive offices: 2533 S Coast Hwy 101, Suite 101, Cardiff CA 92007

     

    2(a)

    Name of person filing:

    Forward Ventures V, L.P., a Delaware Limited Partnership, Forward V Associates, LLC, a Delaware Limited Liability Company, and Standish M. Fleming. The foregoing entities and individuals are collectively referred to as the “Reporting Persons.”

     

    2(b)

    Address or principal business office or, if none, residence:

    c/o Forward Ventures Services, LLC

    9255 Towne Centre Drive, Suite 350

    San Diego, CA 92121

     

    2(c)

    Citizenship:

    U.S.A.

     

    2(d)

    Title of class of securities:

    Common Stock, $0.0001 par value

    2(e) CUSIP No.:

    92765F108

     

    Item 3.

    If this statement is filed pursuant to §§240.13d–1(b) or 240.13d–2(b) or (c), check whether the person filing is a:

     

    (a)

     

    ☐

     

    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

    (b)

     

    ☐

      Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

    (c)

     

    ☐

      Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

    (d)

     

    ☐

      Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a–8);

    (e)

     

    ☐

      An investment adviser in accordance with §240.13d–1(b)(1)(ii)(E);

    (f)

     

    ☐

      An employee benefit plan or endowment fund in accordance with §240.13d–1(b)(1)(ii)(F);

    (g)

     

    ☐

      A parent holding company or control person in accordance with §240.13d–1(b)(1)(ii)(G);

    (h)

     

    ☐

      A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

    (i)

     

    ☐

      A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a–3);

    (j)

     

    ☐

      A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);

    (k)

     

    ☐

      Group, in accordance with §240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution: ________________________________


    Page 3 of 5

     

    Item 4.

    Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    The following information with respect to the ownership of the ordinary shares of the Issuer by the persons filing this Statement is provided as of December 31, 2023:

     

    (a)

    Amount beneficially owned: 2,567,522  .

     

    (b)

    Percent of class: 6.65%  .


       SCHEDULE 13G    Page 4 of 5

     

    (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote

    2,567,522.

     

      (ii)

    Shared power to vote or to direct the vote

    See response to Row 7.

     

      (iii)

    Sole power to dispose or to direct the disposition of 2,664,790.

     

      (iv)

    Shared power to dispose or to direct the disposition of See response to Row 7.

     

    Item 5.

    Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

    Dissolution of a group requires a response to this item.

     

    Item 6.

    Ownership of More than 5 Percent on Behalf of Another Person.

    Under certain circumstances set forth in the limited partnership agreement of Forward Ventures V, L.P. and the limited liability company agreement of Forward GP, the partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from the sale of, shares of the Issuer owned by each such entity of which they are a partner or member.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable

     

    Item 10.

    Certifications

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect other than activities solely in connection with a nomination under § 240.14a-11.


       Page 5 of 5

     

    Signatures

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

        Forward Ventures V, L.P.
    Date: February 13, 2024     Signature:   /s/ Standish M. Fleming
        Name:   Standish M. Fleming
        Title:   Managing Member, Forward V Associates LLC General Partner
        Forward V Associates, LLC
        by:  
        Signature:   /s/ Standish M. Fleming
        Name:   Standish M. Fleming
        Title:   Managing Member
        Signature:   /s/ Standish M. Fleming
        Name:   Standish M. Fleming
    Get the next $VIRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VIRX

    DatePrice TargetRatingAnalyst
    8/16/2024$5.00 → $3.00Outperform → Market Perform
    Leerink Partners
    2/1/2022$10.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $VIRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Viracta Therapeutics Announces Wind Down of Operations

      SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, announced today that the Company has terminated its employees and will wind down operations. The company is also exploring potential strategic alternatives for its development programs. The board of directors appointed Craig R. Jalbert, age 63, as the Company's CEO, President, CFO, Treasurer and Corporate Secretary, and sole member of the board to implement the wind down. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of

      2/5/25 5:00:00 PM ET
      $VIRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viracta Therapeutics Announces New Employment Inducement Grants

      SAN DIEGO, May 17, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that, in connection with the appointment of Michael Faerm as Viracta's new Chief Financial Officer, Viracta's Board of Directors granted Mr. Faerm a non-qualified stock option to purchase 500,000 shares of common stock under Viracta's 2021 Inducement Equity Incentive Plan. Additionally, Viracta's Board of Directors approved the grant of non-qualified stock options to a new non-executive employee to purchase 10,000 shares of common stock. Each optio

      5/17/24 4:05:00 PM ET
      $VIRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer

      SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced the appointment of Michael Faerm as Chief Financial Officer, effective immediately. Mr. Faerm is a seasoned biotech executive with more than 25 years of experience in life sciences companies, equity research and investment banking. "We are delighted to welcome Mike, an accomplished life sciences industry & Wall Street veteran, who we believe will be instrumental in supporting our next phase of development," said Mark Rothera, President and Chief E

      5/14/24 7:00:00 AM ET
      $VIRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VIRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Viracta Therapeutics downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Viracta Therapeutics from Outperform to Market Perform and set a new price target of $3.00 from $5.00 previously

      8/16/24 7:39:54 AM ET
      $VIRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on Viracta Therapeutics with a new price target

      RBC Capital Mkts initiated coverage of Viracta Therapeutics with a rating of Outperform and set a new price target of $10.00

      2/1/22 6:29:36 AM ET
      $VIRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on Viracta Therapeutics with a new price target

      HC Wainwright & Co. initiated coverage of Viracta Therapeutics with a rating of Buy and set a new price target of $35.00

      5/3/21 6:28:40 AM ET
      $VIRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VIRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Viracta Therapeutics Announces Wind Down of Operations

      SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, announced today that the Company has terminated its employees and will wind down operations. The company is also exploring potential strategic alternatives for its development programs. The board of directors appointed Craig R. Jalbert, age 63, as the Company's CEO, President, CFO, Treasurer and Corporate Secretary, and sole member of the board to implement the wind down. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of

      2/5/25 5:00:00 PM ET
      $VIRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives

      SAN DIEGO, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that its Board of Directors has initiated a process to explore a broad range of strategic alternatives. To maximize its cash runway while the Board conducts its review of strategic alternatives, Viracta has elected to close its ongoing pivotal Phase 2 clinical trial of Nana-val in relapsed/refractory EBV+ lymphomas (the NAVAL-1 trial). The company emphasized that its decision to voluntarily close the trial is not the result of any new safety find

      12/26/24 4:30:00 PM ET
      $VIRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

      - Reprioritized resources to reduce costs and enhance focus on Nana-val's development program in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) - - On track to report data from expansion phase of the Phase 2 NAVAL-1 clinical trial of Nana-val in the first half of 2025 - - Determined recommended Phase 2 dose of Nana-val in patients with advanced EBV-positive solid tumors - SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today reported financial

      11/13/24 7:00:00 AM ET
      $VIRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VIRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Viracta Therapeutics Inc.

      SC 13G/A - Viracta Therapeutics, Inc. (0001061027) (Subject)

      11/14/24 4:33:15 PM ET
      $VIRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Viracta Therapeutics Inc.

      SC 13G - Viracta Therapeutics, Inc. (0001061027) (Subject)

      2/13/24 9:04:25 PM ET
      $VIRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Viracta Therapeutics Inc. (Amendment)

      SC 13D/A - Viracta Therapeutics, Inc. (0001061027) (Subject)

      1/10/23 5:21:23 PM ET
      $VIRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VIRX
    Financials

    Live finance-specific insights

    See more
    • Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan

      - New combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial further demonstrate Nana-val's substantial antitumor activity and generally well-tolerated safety profile - - Productive FDA meeting held to align on a potential regulatory path forward for Nana-val in patients with relapsed or refractory EBV-positive PTCL - - Updated Nana-val clinical development plan implemented to optimize its clinical benefit in EBV-positive PTCL patients and expedite a randomized controlled trial to support potential registration - - Viracta to host conference call and webcast on Wednesday, August 14 at 8:

      8/14/24 7:00:00 AM ET
      $VIRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress

      – LENZ Therapeutics to debut on Nasdaq under the ticker symbol "LENZ" as a publicly traded company advancing late clinical-stage assets for the treatment of presbyopia – – Topline data from registration-enabling Phase 3 CLARITY trials for lead assets LNZ100 and LNZ101 expected in April 2024 – – Strong balance sheet with approximately $210 million of cash and cash equivalents, including $53.5 million from a concurrent PIPE financing – LENZ Therapeutics, Inc. (NASDAQ:LENZ) (LENZ or the Company), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced th

      3/21/24 4:30:00 PM ET
      $VIRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VIRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Royston Ivor converted options into 25,219 shares, increasing direct ownership by 3% to 839,741 units (SEC Form 4)

      4 - Viracta Therapeutics, Inc. (0001061027) (Issuer)

      11/27/24 4:08:36 PM ET
      $VIRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Pomerantz Roger converted options into 9,034 shares, increasing direct ownership by 8% to 126,478 units (SEC Form 4)

      4 - Viracta Therapeutics, Inc. (0001061027) (Issuer)

      11/27/24 4:06:38 PM ET
      $VIRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Royston Ivor converted options into 25,219 shares, increasing direct ownership by 3% to 814,522 units (SEC Form 4)

      4 - Viracta Therapeutics, Inc. (0001061027) (Issuer)

      9/12/24 6:13:15 PM ET
      $VIRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VIRX
    SEC Filings

    See more
    • Viracta Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Viracta Therapeutics, Inc. (0001061027) (Filer)

      2/5/25 5:00:32 PM ET
      $VIRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viracta Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Viracta Therapeutics, Inc. (0001061027) (Filer)

      1/31/25 4:30:08 PM ET
      $VIRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viracta Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Events That Accelerate or Increase a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - Viracta Therapeutics, Inc. (0001061027) (Filer)

      1/24/25 5:14:05 PM ET
      $VIRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VIRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Rothera Mark bought $49,362 worth of shares (100,000 units at $0.49) (SEC Form 4)

      4 - Viracta Therapeutics, Inc. (0001061027) (Issuer)

      12/4/23 4:54:41 PM ET
      $VIRX
      Biotechnology: Pharmaceutical Preparations
      Health Care